stopplidelsen/innhold
1
0
Fork 0
Code Issues Pull requests Projects Releases Packages Wiki Activity Actions

Add content and translations

Browse source
This commit is contained in:
Ruben 2025-12-12 21:53:19 +01:00
parent a273a7a7a0
commit f949439ebf
49 changed files with 1192 additions and 346 deletions
Download patch file Download diff file Expand all files Collapse all files

67
content/faq/resept-norge/article.en.md Normal file
View file

@ -0,0 +1,67 @@
# Can you get medical cannabis on prescription in Norway?
Obtaining a prescription for medical cannabis in Norway remains extremely difficult under current regulations. The medication category is classified as "experimental treatment," which discourages most doctors from prescribing it unless part of a clinical study.
However, some options do exist depending on the type of physician:
**General practitioners (GPs) can prescribe the following (without reimbursement):**
- Sativex and Epidyolex (approved cannabis-based medicines)
- CBMP products containing less than 1% THC (exemption via the Norwegian Medicines Agency)
- Products with less than 10 mg/ml THC (considered equivalent to less than 1%)
For a detailed overview of available options, see *"Types of medical cannabis available in Norway."*
GPs can also provide a referral letter for patients to consult foreign doctors regarding medical cannabis as a potential treatment. A template for this referral is available on the Norwegian Medicines Agency's website (link in comments).
**Specialists working in hospitals** (both public and private) can prescribe all cannabis-based products. Prescriptions from public hospitals qualify for cost reimbursement under the H-prescription scheme, though many public hospitals have stopped issuing these prescriptions to reduce expenses. If prescribed by a specialist at a private hospital, the patient must cover the full cost.
Both Sativex and Epidyolex are approved medicines in Norway. Sativex is indicated for MS-related spasms, while Epidyolex is approved for Dravet syndrome, Lennox-Gastaut syndrome, and seizures associated with tuberous sclerosis. These medications can also be prescribed off-label for other conditions. Costs are covered under the H-prescription scheme if prescribed by a public hospital specialist (Sativex was added to this scheme on February 1, 2021, and Epidyolex on August 1, 2018). If prescribed by other doctors, patients must pay out of pocket.
Pricing for these medications typically starts at around NOK 900 for dried plant material and NOK 4,000 or more for oils.
**Conditions approved for exemption by the Norwegian Medicines Agency (as of 2023):**
| Condition | CBD | CBD/THC | THC |
|----------------------------|-----|---------|-----|
| ADHD | ✓ | | |
| Appetite stimulation | | | ✓ |
| Autism | ✓ | | |
| Hypertension | ✓ | | |
| Crohn’s disease | | | ✓ |
| Cluster/migraine/headache | ✓ | | ✓ |
| CRPS | | | ✓ |
| Epilepsy | ✓ | | |
| Fatigue/ME | | | ✓ |
| Fibromyalgia | ✓ | | |
| Hiccups | ✓ | | |
| Cancer-related | ✓ | | ✓ |
| Nausea | ✓ | | |
| Palliative care | | ✓ | |
| ME | ✓ | | |
| Multiple sclerosis | ✓ | | ✓ |
| Muscular dystrophy | | | ✓ |
| Palliative care | | | ✓ |
| Parkinson’s disease | ✓ | | |
| Psoriasis | ✓ | | |
| Psychiatric conditions | | | ✓ |
| PTSD | ✓ | | ✓ |
| Low platelet count | ✓ | | |
| Restless legs syndrome | ✓ | | ✓ |
| Rheumatism | ✓ | | |
| Complex conditions | | | ✓ |
| Schizophrenia | ✓ | | |
| Tremors | ✓ | | ✓ |
| Pain | ✓ | ✓ | ✓ |
| Spasms/cramps | ✓ | ✓ | ✓ |
| Stress/anxiety | ✓ | | ✓ |
| Wound healing | ✓ | | |
| Sleep disorders | ✓ | | ✓ |
| Tics | | | ✓ |
| Tourette’s syndrome | | | ✓ |
**Key sources:**
- [Regulations on the requisition of prohibited narcotics and certain medicines for human use - Lovdata](https://lovdata.no/dokument/SF/forskrift/2022-09-22-1630)
- [Cannabis treatment under current regulations - Norwegian Medicines Agency](https://www.dmp.no/godkjenningsfritak/for-leger-og-tannleger/legemidler-det-ofte-er-sporsmal-om-ved-godkjenningsfritak/behandling-med-cannabis-innenfor-dagens-regelverk)
- [Bringing medicines into Norway - Norwegian Medicines Agency](https://www.dmp.no/tilvirkning-import-og-salg/import-av-legemidler-til-personlig-bruk/legemidler-pa-reise-inn-til-norge#Legemidler-med-narkotiske-virkestoffer-3)
The sections on *"Medicines with narcotic substances"* and *"CBD (cannabidiol)"* are particularly relevant.

56
content/faq/resept-norge/article.md
View file

@ -1,10 +1,4 @@
# Får man medisinsk cannabis på resept i Norge?
## Spørsmål
Er det mulig å få medisinsk cannabis på resept i Norge?
## Svar
# Kan man få medisinsk cannabis på resept i Norge?
Det er nesten umulig å få resept på medisinsk cannabis i Norge i dag. Dette henger sammen med at medikamentgruppen er definert som "utprøvende behandling". Det gjør at leger vegrer seg for å skrive ut resept, dersom det ikke skjer i forbindelse med en studie.
@ -12,11 +6,9 @@ Men det finnes likevel noen alternativer, avhengig av lege:
Fastlege kan skrive ut følgende produkter (uten refusjon):
· Sativex og Epidyolex (registerte cannabis-legemidler).
· CBMP-produkter med mindre enn 1 % THC (godkjenningsfritak via DMP).
· Produkter med mindre enn 10 mg/ml THC (dette regnes som mindre enn 1 %).
– Sativex og Epidyolex (registerte cannabis-legemidler).
- CBMP-produkter med mindre enn 1 % THC (godkjenningsfritak via DMP).
- Produkter med mindre enn 10 mg/ml THC (dette regnes som mindre enn 1 %).
For en nærmere oversikt over tilgjengelige varianter se "Typer medisinsk cannabis tilgjengelig i Norge"
@ -30,14 +22,48 @@ Kostnader til medikamentgruppen er cirka kroner 900,- for tørket plantematerial
Diagnoser og tilstander som allerde har fått godkjenningsfritak hos Direktoratet for medisinske produker (tidligere Legemiddelverket) er følgende per 2023:
![](./diagnoser-Norge.jpg)
| Diagnose/tilstand | CBD | CBD/THC | THC |
|----------------------------|-----|---------|-----|
| ADHD | ✓ | | |
| Apetitt | | | ✓ |
| Autisme | ✓ | | |
| Blodtrykksykdom | ✓ | | |
| Crohns | | | ✓ |
| Cluster/migrene/hodepine | ✓ | | ✓ |
| CRPS | | | ✓ |
| Epilepsi | ✓ | | |
| Fatigue/ME | | | ✓ |
| Fibromyalgi | ✓ | | |
| Hicka | ✓ | | |
| Kreftrelatert | ✓ | | ✓ |
| Kvalme | ✓ | | |
| Lindrende | | ✓ | |
| ME | ✓ | | |
| MS | ✓ | | ✓ |
| Muskeldystrofi | | | ✓ |
| Palliativ | | | ✓ |
| Parkinson | ✓ | | |
| Psoriasis | ✓ | | |
| Psykiske tilstander | | | ✓ |
| PTSD | ✓ | | ✓ |
| Reduserte blodplater | ✓ | | |
| Restless legs | ✓ | | ✓ |
| Reumatisme | ✓ | | |
| Sammensatte tilstander | | | ✓ |
| Schizofreni | ✓ | | |
| Skjelving/tremor | ✓ | | ✓ |
| Smerte | ✓ | ✓ | ✓ |
| Spasmer/kramper | ✓ | ✓ | ✓ |
| Stress/uro/angst | ✓ | | ✓ |
| Sårbehandling | ✓ | | |
| Søvnproblemer | ✓ | | ✓ |
| Tics | | | ✓ |
| Tourettes | | | ✓ |
Sentrale kilder:
- [Forskrift om rekvirering av forbudt narkotikum og bestemte legemidler til humanmedisinsk bruk - Lovdata](https://lovdata.no/dokument/SF/forskrift/2022-09-22-1630)
- [Behandling med cannabis innenfor dagens regelverk - Direktoratet for medisinske produkter](https://www.dmp.no/godkjenningsfritak/for-leger-og-tannleger/legemidler-det-ofte-er-sporsmal-om-ved-godkjenningsfritak/behandling-med-cannabis-innenfor-dagens-regelverk)
- [Legemidler på reise inn til Norge - Direktoratet for medisinske produkter(https://www.dmp.no/tilvirkning-import-og-salg/import-av-legemidler-til-personlig-bruk/legemidler-pa-reise-inn-til-norge#Legemidler-med-narkotiske-virkestoffer-3)
Her er det spesielt kapitlene som omhandler «Legemidler med narkotiske virkestoffer» og «CBD (cannabidiol)» som er av størst interesse

3
content/faq/resept-norge/metadata.ini
View file

@ -1 +1,4 @@
summary = "Det er nesten umulig å få medisinsk cannabis på resept i Norge fordi det er definert som utprøvende behandling. Fastlege kan skrive ut produkter med under 1% THC, mens spesialist på sykehus kan skrive ut alle produkter, men med begrensede refusjonsordninger."
[en]
summary = "Obtaining medical cannabis by prescription in Norway is extremely difficult as it is classified as experimental treatment. general practitioners can only prescribe products with less than 1% THC, while hospital specialists may prescribe any product—but with limited reimbursement options."